medigraphic.com
ISSN 2992-8559 (Electronic)
ISSN 1405-0625 (Print)

2012, Number 1

<< Back Next >>

Cir Plast 2012; 22 (1)

Keloid scar: imiquimod effectivity compared to as a therapeutic

Martínez MJR, Ortiz LJB

Language: Spanish
References: 65
Page: 22-32
PDF size: 498.10 Kb.


ABSTRACT

The keloid scar is a pathological lesion characterized by excessive proliferation of collagen in the papillary dermis that surpasses the original edges of the wound. Twenty cases of keloid scar were studied (60% women [n = 12] and 40% men [n = 8]) with an average age of 33 over a one year follow-up (May 2010 - May 2011). The lesions were described using the parameters of the Vancouver scale. Surgical resection was performed and a simple random selection divided the group into 2 groups: Group A was treated with Imiquimod cream 5% c/24 h for 8 weeks and Group B: Triamcinolone 10 - 40 mg/mL each month (4 applications). Patients were checked on day 7, two weeks and 4 weeks afterwards, then monthly during the first semester and a year after the procedure. General improvement in the appearance and characteristics of the scar was noted with statistical significance (t = 8. 320, gl = 19, p ‹ 0.05). Comparatively in both groups statistical difference could also be documented in favor of Imiquimod (F = 8. 337, gl = 9, p ‹ 0.05) compared to Triamcinolone (F = 4. 743, gl = 9, p ‹ 0.05), also that both groups achieved a favorable tendency in terms of the characteristics of the scar and decline in the scale of Vancouver.


REFERENCES

  1. Niessen FB, Spauwen PHM, Schalwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 1999; 104: 1435-1458.

  2. Rockwell W, Cohen I, Erlich H. Keloids and hypertrophic scars. A comprehensive review. Plast Reconstr Surg 1989; 84: 827-837.

  3. Widgerow AD, Chait LA, Stals R, Stals PJ. New innovations in scar management. Aesthetic Plast Surg 2000; 24: 227-234.

  4. Louw L. The keloid phenomenon: Progress toward a solution. Clinical Anatomy 2007; 20:3-14.

  5. Datuba-Brown DD. Keloids: A Review of the Literature. Br J Plast Surg 1990; 43: 70-77.

  6. Bayat A. Genetic susceptibility to keloid disease: mutation screening of the TGFB3 gene. Br J Plast Surg 2005; 58: 914-921.

  7. Cosman B, Crikelair GF, Ju DM. The surgical treatment of keloids. Plast Reconstr Surg 1961; 27: 335-358.

  8. Younai S, Nichter LS, Wellisz T, Reinisch J, Nimni ME, Tuan TL. Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. Ann Plast Surg 1994; 33: 148-151.

  9. Kischer CW, Wagner HN. Increased fibronectin production by cell lines from hypertrophic scar and keloid. Connect Tissue Res 1989; 23: 279-288.

  10. Pearlstein E, Gold LI, Garcia-Prado A. Fibronectin: a review of its structure and biological activity. Mol Cell Biochem 1980; 29: 103-108.

  11. Alaish S, Yager D. Hyaluronic acid metabolism in keloid fibroblasts. J Pediatr Surg 1995; 30: 949-952.

  12. Hunzelmann N, Anders S. Co-ordinate induction of collagen type I and biglycan expression in keloids. Br J Dermatol 1996; 135: 394-399.

  13. Andriessen M, Niessen F. Hypertrophic scarring is associated with epidermal abnormalities: An immunohistochemical study. J Pathol 1998; 186: 192-200.

  14. Kischer CW. The microvessels in hypertrophic scars, keloids and related lesions. J Submicros Cytol Pathol 1992; 24: 281-283.

  15. Friedman D, Boyd C. Regulation of collagen gene expression in keloids and hypertrophic scars. J Surg Res 1993; 55: 214-222.

  16. Russell SB, Trupon KM. Reduced growth factor requirements of keloid derived fibroblasts may account for tumor growth. Proc Natl Acad Sci USA 1988; 85: 587-591.

  17. Curtis A, Seehar G. The control of cell division by tension or diffusion. Nature 1978; 274:52-53.

  18. Cohen J, McCoy B. Immunoglobulin, complement and histocompatibility antigen studies in keloid patients. Plast Reconstr Surg 1979; 63: 689-695.

  19. Kazeem A. The immunological aspects of keloid tumor formation. J Surg Oncol 1988; 38:16-18.

  20. Yagi KI, Dafalla AA, Osman AA. Does an immune reaction to sebum in wounds cause keloid scars? Beneficial effect of desensitisation. Br J Plast Surg 1979; 32: 223-227.

  21. Fong E, Chyne L. Keloids: time to dispel the myths. Plast Recons Surg 1999; 104: 1199-1202.

  22. Lindsey WH. Facial Keloids. A 15-year experience. Arch Otolatyngol Head and Neck Surg 1997; 123: 397-400.

  23. Mafong EA, Ashinoff R. Treatment of hypertrophic scars and keloids: a review. Aesth Surg J 2000; 20: 114-121.

  24. Alhady SM. Keloids in various races. A review of 175 cases. Plast Reconstr Surg 1969; 44:564-566.

  25. Ogawa R, Akaishi S. Differential and exclusive diagnosis of diseases that resemble keloids and hypertrophic scars. Ann Plast Surg 2009; 62: 660-664.

  26. Sabater-Marco V, Pérez-Valles A. Sclerosing dematofibrosarcoma protruberans (DFSP): an unusual variant with focus on the histopathologic differential diagnosis. Int J Dermatol 2006; 45: 59-62.

  27. Mustoe TA, Cooter RD, Gold MH et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560-571.

  28. Baker BL. Withaker WL. Interference with wound healing by local action of adrenocortical steroids. Endocrinology 1950; 46: 544-551.

  29. Conway H, Stark R. ACTH in plastic surgery. Plast Reconstr Surg 1951; 8:354-377.

  30. Hollander A. Intralesional injections of triamcinolone acetonide: A therapy for dermatoses. Antibiotic Med Clin Ther 1961; 8: 78-81.

  31. Carrol LA, Hanasono MM. Triamcinolone stimulates βFGF production and inhibits TGF-b1 productions by human dermal fibroblast. Dermatol Surg 2002; 28: 704-709.

  32. Dishi Y, Fu ZW. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, colagenase, and tissue inhibitors of metalloproteinase. Br J Dermatol 2002; 147: 859-868.

  33. Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy induced skin atrophy. Exp Dermatol 2006; 15: 406-420.

  34. Fardel L, Flahault A. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient opinion. Br J Dermatol 2007; 157: 142-148.

  35. Griffith H. The treatment of keloid with triamcinolone acetonide. Plast Reconstr Surg 1966; 38: 202-208.

  36. Griffith H. A follow-up study on the treatment of keloid with triamcinolone acetonide. Plast Reconstr Surg 1970; 46: 145-150.

  37. Ketchum L. The treatment of hypertrophic scar, keloid and scar contracture by triamcinolone acetonide. Plast Reconstr Surg 1966; 38: 209-218.

  38. Ketchum L. A follow-up on treatment of hypertrophic scar and keloid with triamcinolone acetonide. Plast Reconstr Surg 1971; 48: 256-259.

  39. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984; 74: 1112–1116.

  40. Berman B, Duncan MR. Short-term keloid treatment in vivo with interferon alfa 2-b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989; 21: 694-706.

  41. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL et al. Self-administered topical 5% imiquimod cream for external anogenital warts for Human Papilloma Virus. Arch Dermatol 1998; 134: 25-30.

  42. Beutner KR. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol 1999; 41: 1002-1007.

  43. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-S11.

  44. Macedo L, Pinhal-Enfield G. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol 2007; 171: 1774-1788.

  45. Underhill DM. Collaboration between the innate immune receptors dectin-1, TLRs and Nods. Immunol Rev 2007; 219: 75-87.

  46. Pavsner-Fischer M. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-1432.

  47. Wang R, Town T. HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated TLR-7 and upregulating p38 MAPK and p13K pathways. J Sur Res 2006; 136: 58-69.

  48. Takeda K, Kashio T. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.

  49. Krajewski A, Garg M, De M, and Chandawarkar RY. Phagocytosis: Reemerging roles for a primitive function. Plast Reconstr Surg 2009; 123: 834-847.

  50. Susuki H, Wang B. Imiquimod, a topical immune response modifier induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.

  51. Skinner RB. Imiquimod. Dermatol Clin 2003; 21:291-300.

  52. Garland SM. Imiquimod. Curr Opin Infect Dis 2003; 16: 85-89.

  53. Schön M. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signalling in TLR-7 y TLR-8 independent fashion. J Invest Dermatol 2006; 126: 1338-1347.

  54. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.

  55. Sullivan GW, Linden J. Role of A2A adenosine receptors in inflammation. Drug Dev Res 1998; 45: 103-112.

  56. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003; 121: 1205-1209.

  57. Schön MP, Schön M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004; 9: 291-298.

  58. Mahoney MH, Joseph, M. Topical Imiquimod therapy for lentigo maligna. Ann Plast Surg 2008; 61: 419-424.

  59. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47: S209-211.

  60. Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg 2003; 29: 1050-1.

  61. Hochman, B, Locali RF, Matsuoka PK, Ferreira LM. Intralesional Triamcinolone Acetonide for Keloid Treatment: A Systematic Review. Aesth Plast Surg 2008; 32: 705-709.

  62. Baryza MJ, Baryza GA. The Vancouver scar scale: An Administration Tool and Its Interrater Reliability. J Burn Care Rehabil 1995; 16: 535-538.

  63. Bond J, Duncan JA, Sattar A et al. The maturation of the human scar: an observational study. Plast Reconstr Surg 2008; 121: 1650-1658.

  64. Maeda K. Painless injections technique of local infiltration anesthesia and prevention and treatment of adverse reaction of local anesthetics. J Jpn Soc Aesth Plast Surg 1991; 13: 89-95.

  65. Rosen DJ, Patel MK, Freeman K, Weiss PR. A primary protocol for the management of ear keloids: results of excision combined with intraoperative and postoperative steroid injections. Plast Reconstr Surg 2007; 120: 1395-1400.




2020     |     www.medigraphic.com